Histidine-rich glycoprotein (HRG) as a novel biomarker to predict Dengue Hemorrhagic Fever /Dengue Shock Syndrome (DHF/DSS).

Dengue infection has become a global problem with potential complications causing death in the form of Dengue Haemorrhagic Fever (DHF) / Dengue Shock Syndrome (DSS). Until now, there is no biomarker that can specifically predict the occurrence of DHF/DSS. Histidine-rich glycoprotein (HRG) is reported to have a protective effect on immune cells, endothelial cells and platelet cells that play a central role in the DHF /DSS immunopathogenesis process.

HRG becomes a potential target as a biomarker because of its interaction with various protein targets and receptors expressed in various cells directly involved in DHF/DSS immunopathogenesis. The relationship between the concentration of HRG and Zinc in the plasma of patients infected with Dengue virus with DHF / DSS will be analyzed together with signs of primary/secondary infection, genotype of Dengue virus and endothelial cell dysfunction.

This research is still in line with the purpose of previous research to evaluate the potential of HRG as a biomarker to predict the occurrence of DHF/DSS together with Zinc which affects the biological activity of HRG related to the etiopathogenesis of dengue infection. However, current research focused on the role of receptors and its interaction with HRG spesifically in the immune cells. Understanding the role of HRG in the progression of Dengue infection also opens opportunities for applied studies to explore the use of HRG protein as a specific supportive therapy for the prevention of DHF / DSS. This can broaden the modality of supportive treatment options that can more specifically prevent the progression and mortality of dengue infection.